STMN1 (Ab-25) Antibody

What is STMN1 and why is it significant in cellular research?

STMN1 (Stathmin 1) is a ubiquitous cytosolic phosphoprotein that functions as an intracellular relay integrating regulatory signals within the cellular environment. It plays a critical role in the regulation of the microtubule filament system by destabilizing microtubules, preventing their assembly and promoting disassembly. This functionality makes STMN1 significant in research related to cell cycle regulation, particularly in mitotic entry and progression. Phosphorylation at Ser-16 appears necessary for axon formation during neurogenesis, and the protein is implicated in the control of learned and innate fear responses according to recent studies. STMN1 has attracted considerable attention in cancer research due to its role in cell proliferation and potential connections to malignant transformation .

What are the key molecular characteristics of STMN1 that researchers should be aware of?

Researchers should be familiar with several key aspects of STMN1: it has a molecular weight of approximately 17-19 kDa and is known by several alternative names including LAP18, OP18, Metablastin, and Oncoprotein 18. The protein contains multiple phosphorylation sites, with serine residues at positions 16, 25, 38, and 63 being particularly important for its regulation and function. The STMN1 gene is located on chromosome 1p36.11 and encodes multiple transcript variants resulting in different isoforms. The protein's UniProt ID is P16949, which is useful for cross-referencing in databases. Understanding these molecular characteristics is essential for experimental design, particularly when selecting appropriate antibodies and interpreting results in the context of post-translational modifications .

What are the optimal conditions for using STMN1 (Ab-25) antibody in Western blot applications?

For optimal Western blot results with STMN1 (Ab-25) antibody, researchers should adhere to the following protocol: Use a dilution range of 1:500-1:1000 in standard blocking buffer (typically 5% BSA or non-fat milk in TBST). When preparing samples, include phosphatase inhibitors if studying phosphorylated forms of STMN1 to prevent dephosphorylation during extraction. Use fresh samples or aliquoted lysates to avoid protein degradation. The predicted band size for STMN1 is approximately 17 kDa, though slight variations may occur depending on post-translational modifications. For loading controls, consider using housekeeping proteins with molecular weights distinct from STMN1 to avoid overlap. When validating antibody specificity, include positive controls such as Jurkat cell extracts, particularly those treated with PMA which enhances phosphorylation at S25. For enhanced detection of low abundance STMN1, consider using chemiluminescent substrates with extended sensitivity range and optimize exposure times accordingly .

What sample preparation methods ensure optimal preservation of STMN1 phosphorylation states?

Preserving STMN1 phosphorylation states requires careful attention to sample preparation. Begin by harvesting cells quickly, preferably using direct lysis in ice-cold buffer containing both protease and phosphatase inhibitor cocktails. Include specific phosphatase inhibitors such as sodium fluoride (50 mM), sodium orthovanadate (1 mM), and β-glycerophosphate (10 mM) to effectively preserve phosphorylation at S25 and other sites. Maintain samples at 4°C throughout processing to minimize enzymatic activity. Avoid repeated freeze-thaw cycles which can lead to protein degradation and loss of phosphorylation signal. For tissue samples, snap-freezing in liquid nitrogen immediately after collection is essential, followed by homogenization in cold lysis buffer containing the inhibitors mentioned above. When working with paraffin-embedded tissues for immunohistochemistry, use phospho-specific antigen retrieval methods, typically involving citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), with optimization required for different tissue types. Finally, quantify protein concentration and standardize loading to ensure comparable results across experimental conditions .

How should researchers optimize immunohistochemistry protocols for STMN1 (Ab-25) antibody in different tissue types?

Optimizing immunohistochemistry protocols for STMN1 (Ab-25) antibody requires tissue-specific considerations. Begin with a systematic approach to antigen retrieval, testing both heat-induced epitope retrieval methods using citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) at different temperatures (95-100°C) and durations (10-30 minutes). For formalin-fixed paraffin-embedded tissues, dilution ranges from 1:50 to 1:200 are recommended as starting points, with optimization necessary for each tissue type. Blocking steps should be extended (1-2 hours) with 5-10% normal serum from the same species as the secondary antibody to minimize background staining. For highly vascularized tissues or those with endogenous peroxidase activity, include an additional blocking step with hydrogen peroxide. When examining tissues with high background potential, consider implementing a biotin-streptavidin amplification system or tyramide signal amplification for low abundance targets. Validation should include appropriate negative controls (primary antibody omission, isotype controls) and positive controls (human breast carcinoma tissue has been documented to express STMN1). For multiplex immunohistochemistry, carefully select antibody combinations that avoid cross-reactivity and optimize the sequence of antibody application .

How can STMN1 (Ab-25) antibody be effectively utilized in studying cancer progression mechanisms?

STMN1 (Ab-25) antibody serves as a valuable tool for investigating cancer progression mechanisms through multiple experimental approaches. Researchers can employ this antibody to conduct immunohistochemical analyses of tumor tissue microarrays to correlate STMN1 expression or phosphorylation status with clinical parameters such as tumor stage, grade, and patient outcomes. When combined with phospho-specific STMN1 antibodies, researchers can map the spatial distribution of active versus inactive STMN1 within the tumor microenvironment. For studying metastatic potential, co-staining with markers of epithelial-mesenchymal transition alongside STMN1 can reveal associations between STMN1 expression and invasive phenotypes. In cell culture models, time-course experiments using STMN1 (Ab-25) antibody following treatment with various therapeutic agents can reveal changes in STMN1 expression or phosphorylation as potential biomarkers of treatment response. Additionally, chromatin immunoprecipitation followed by sequencing (ChIP-seq) experiments using transcription factor antibodies can identify regulators of STMN1 expression in cancer cells, providing insights into the upstream control of this oncogenic protein .

What are the critical considerations when using STMN1 (Ab-25) antibody in proximity ligation assays to study protein-protein interactions?

When implementing proximity ligation assays (PLA) with STMN1 (Ab-25) antibody, researchers must address several critical factors. First, antibody compatibility is paramount—the STMN1 (Ab-25) antibody must be paired with interaction partner antibodies raised in different species to enable species-specific secondary antibody recognition. Careful titration of both antibodies is essential, with recommended starting dilutions of 1:100-1:200 for the STMN1 antibody, optimizing to achieve sufficient sensitivity while minimizing background. Validate the specificity of the STMN1-partner interaction using appropriate controls, including omission of primary antibodies and use of cells where either protein is knocked down. For studying dynamic interactions, consider fixation methods that preserve transient protein complexes; paraformaldehyde (4%) fixation for 10-15 minutes is generally suitable, but glutaraldehyde may better preserve certain cytoskeletal interactions involving STMN1. When studying microtubule-related interactions, pre-extraction protocols that remove soluble proteins can enhance detection of microtubule-bound STMN1 complexes. Finally, quantitative analysis should include both the number of PLA signals per cell and their subcellular distribution, as STMN1 interactions may occur differently in nuclear, cytoplasmic, or membrane-proximal regions .

How should researchers interpret unexpected molecular weight variations when detecting STMN1 using the Ab-25 antibody?

When encountering unexpected molecular weight variations in STMN1 detection, researchers should systematically evaluate several potential explanations. While the predicted molecular weight of STMN1 is approximately 17 kDa, bands may appear at different positions due to post-translational modifications. Phosphorylation at multiple sites (S16, S25, S38, S63) can cause significant mobility shifts, typically resulting in bands at 19-21 kDa. To confirm these are phosphorylated forms, researchers should treat samples with lambda phosphatase and observe band migration patterns. Alternative splice variants of STMN1 may also present at different molecular weights; comparing expression patterns across multiple cell lines can help identify tissue-specific isoforms. If detecting bands at substantially higher molecular weights (>25 kDa), consider potential protein complexes that may be incompletely denatured—try increasing SDS concentration or boiling time in sample preparation. Additionally, ubiquitination or other modifications may cause higher molecular weight species. Validate unexpected bands through complementary approaches such as mass spectrometry or by using multiple antibodies targeting different epitopes of STMN1. Finally, compare results from reducing versus non-reducing conditions, as STMN1 contains cysteine residues that may form disulfide bonds affecting mobility .

What are the potential sources of variability in STMN1 phosphorylation detection and how can they be controlled?

Variability in STMN1 phosphorylation detection stems from multiple sources that must be systematically controlled. Cell culture conditions significantly impact phosphorylation status—serum starvation, cell density, and time post-plating can all alter baseline phosphorylation. Standardize these parameters across experiments and include appropriate positive controls (e.g., PMA treatment for S25 phosphorylation). Sample handling introduces another source of variability—phosphatases remain active during cell lysis unless properly inhibited. Use freshly prepared lysis buffers containing phosphatase inhibitor cocktails and maintain samples at 4°C throughout processing. The specificity of phospho-antibodies may vary between lots and manufacturers, necessitating validation with phosphatase-treated negative controls and phosphomimetic mutant-expressing positive controls. Additionally, antibody cross-reactivity with similar phospho-epitopes on other proteins should be evaluated using STMN1 knockout or knockdown samples. For quantitative western blotting, normalize phospho-STMN1 signal to total STMN1 rather than housekeeping proteins to account for expression variations. When comparing phosphorylation across experimental conditions, include internal reference samples on each blot to control for inter-blot variability. Finally, for tissue analyses, consider fixation timing and methods, as delayed fixation can result in rapid dephosphorylation of labile phosphosites .

How can researchers differentiate between specific and non-specific binding when using STMN1 (Ab-25) antibody in their experiments?

Distinguishing specific from non-specific binding when using STMN1 (Ab-25) antibody requires implementing a multi-layered validation strategy. First, perform antibody validation using positive and negative biological controls: cell lines with confirmed high STMN1 expression (e.g., Jurkat, HeLa cells) versus those with STMN1 knockdown/knockout. For immunohistochemistry and immunofluorescence applications, include isotype control antibodies from the same species at identical concentrations to identify non-specific binding. Peptide competition assays provide another validation approach—pre-incubating the antibody with excess immunizing peptide (the I-L-S-P-R sequence) should abolish specific binding while non-specific interactions remain. When interpreting western blot results, compare the detected band pattern with the predicted molecular weight (17 kDa) and confirm single band specificity. If multiple bands appear, perform subcellular fractionation to determine if different bands represent compartment-specific forms of STMN1. For immunoprecipitation experiments, compare results using the STMN1 (Ab-25) antibody for pull-down followed by detection with a different STMN1 antibody targeting a separate epitope. Additionally, cross-validate results using orthogonal detection methods such as mass spectrometry to confirm the identity of detected proteins. Finally, when analyzing experimental data, maintain consistent imaging parameters and quantification methods to ensure signal specificity is consistently evaluated across all samples .

What multiplex immunofluorescence strategies can be employed to study STMN1 interactions with the microtubule network?

Advanced multiplex immunofluorescence strategies can effectively elucidate STMN1 interactions with the microtubule network while minimizing cross-reactivity issues. Sequential staining protocols represent an optimal approach, beginning with the detection of phosphorylated STMN1 using the primary antibody at 1:100-1:200 dilution, followed by fluorophore-conjugated secondary antibody application. After thorough washing, implement a blocking step with unconjugated secondary antibodies matching the species of the first primary antibody to prevent cross-reactivity before proceeding to tubulin staining. For co-visualization with microtubule plus-end binding proteins (e.g., EB1, CLIP170), employ antibodies raised in different species than the STMN1 antibody to enable clear discrimination. When studying dynamic processes, consider implementing live-cell imaging approaches combining fluorescently-tagged tubulin (e.g., SiR-Tubulin) with cells expressing fluorescent protein-tagged STMN1, followed by fixation and retrospective immunostaining with phospho-specific antibodies. For super-resolution microscopy applications, stochastic optical reconstruction microscopy (STORM) or structured illumination microscopy (SIM) provide the nanoscale resolution necessary to visualize STMN1-microtubule interactions, requiring specific fluorophore selection (e.g., Alexa Fluor 647, Atto 488) optimized for these techniques. To capture transient interactions, implement proximity ligation assays between STMN1 and tubulin, generating punctate signals only when proteins are within 40 nm of each other. Finally, quantitative image analysis should include colocalization metrics (Pearson's coefficient, Manders' overlap coefficient) and distance mapping between STMN1 and microtubule structures across different experimental conditions .

What are the most common technical challenges when using STMN1 (Ab-25) antibody in flow cytometry and how can they be overcome?

When implementing STMN1 (Ab-25) antibody in flow cytometry, researchers encounter several common technical challenges. The primary difficulty involves accessing the intracellular epitope, requiring optimization of fixation and permeabilization protocols. For optimal results, use freshly prepared 2-4% paraformaldehyde for 10-15 minutes at room temperature, followed by permeabilization with 0.1-0.5% Triton X-100 or 90% methanol (pre-chilled to -20°C). Methanol often provides superior results for nuclear proteins and phosphoepitopes but may denature certain antigens. Another frequent challenge is high background signal, which can be addressed by implementing a more stringent blocking protocol using 5-10% normal serum corresponding to the secondary antibody species, combined with 0.1-0.5% BSA. Incubate cells in blocking solution for 30-60 minutes before antibody addition. For antibody concentration, begin with a 1:50-1:100 dilution and perform titration experiments to identify optimal signal-to-noise ratio. When analyzing phosphorylation states, rapid epitope loss during processing remains problematic; maintain samples at 4°C throughout and include phosphatase inhibitors in all buffers. For multi-parameter analysis, carefully select fluorophores to minimize spectral overlap with other markers, particularly when combining with cell cycle dyes like DAPI or PI. Finally, include appropriate controls: isotype controls at matching concentrations, negative controls (STMN1-knockdown cells), and positive controls (cells treated with microtubule-disrupting agents that alter STMN1 phosphorylation) .

How can researchers validate the specificity of STMN1 (Ab-25) antibody across different experimental systems?

Validating STMN1 (Ab-25) antibody specificity requires implementing a systematic approach across multiple experimental systems. Begin with genetic validation using STMN1 knockout or knockdown models—the antibody signal should be significantly reduced or eliminated in these systems compared to wild-type controls. For knockout validation, CRISPR-Cas9-mediated STMN1 deletion provides the most definitive control. When genetic manipulation is not feasible, peptide competition assays serve as an alternative validation method; pre-incubating the antibody with excess immunizing peptide (ILSPR sequence) should abolish specific staining. Cross-platform validation represents another critical approach—the antibody should detect STMN1 consistently across different techniques (western blot, immunohistochemistry, immunofluorescence) with appropriate optimization for each method. For western blotting, size validation is essential; the detected band should correspond to the predicted molecular weight of 17-19 kDa. When unexpected bands appear, mass spectrometry analysis of immunoprecipitated material can confirm protein identity. Species cross-reactivity claims should be verified experimentally in relevant model organisms, as sequence conservation may not guarantee epitope accessibility. For phospho-specific detection, treatment with lambda phosphatase should eliminate signal if the antibody is truly phosphorylation-dependent. Finally, reproducibility validation across different lots of the same antibody is crucial for longitudinal studies, potentially requiring side-by-side comparison when transitioning between antibody batches .